Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Childhood Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 71.4%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Retinoic acid post‐consolidation therapy vs no further treatment

Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT

Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
HR 0.87 [0.46, 1.63]
1 study · 98 participants
Low

Retinoic acid post‐consolidation therapy vs no further treatment

Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT

Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
HR 0.86 [0.5, 1.49]
1 study · 98 participants
Low

Retinoic acid post‐consolidation therapy vs no further treatment

Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Retinoic acid post‐consolidation therapy vs no further treatment

Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT

The review found no eligible studies for this question.

1 finding from 1 review

Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found